What Is the Most Accurate Test for Sjögren’s Syndrome?

No single test diagnoses Sjögren’s syndrome with perfect accuracy, but two carry far more diagnostic weight than anything else: a blood test for anti-SSA/Ro antibodies and a minor salivary gland biopsy. Under the current international classification system, these two tests each score the highest points toward a diagnosis, and most confirmed cases rest on one or both. The challenge is that Sjögren’s affects multiple organs in different patterns across different people, so the diagnostic path usually involves combining several tests rather than relying on any one alone.

Anti-SSA Antibodies and Why They Matter Most

If you could order only one test for suspected Sjögren’s, most rheumatologists would pick anti-SSA/Ro antibodies. Under the 2016 ACR-EULAR classification criteria, a positive anti-SSA/Ro result carries three points out of the four needed for classification, making it the single highest-weighted item. These antibodies target proteins called Ro52 and Ro60, and their presence strongly correlates with the inflammatory gland damage that defines the disease.

Anti-SSA testing is a standard blood draw, widely available, and relatively inexpensive. It is also the test most likely to push a diagnosis across the finish line without requiring an invasive procedure. That said, not every person with Sjögren’s produces these antibodies. Roughly 15 to 30 percent of patients are “seronegative,” meaning their blood tests come back negative for anti-SSA despite having the disease. For those individuals, biopsy becomes essential.

What About Anti-SSB Antibodies?

Anti-SSB/La antibodies have been part of Sjögren’s testing for decades, and many labs still report them alongside anti-SSA. But their standalone diagnostic value has been seriously questioned. The 2016 ACR-EULAR criteria dropped anti-SSB entirely, based on evidence that patients who test positive for anti-SSB but negative for anti-SSA rarely show the hallmark features of the disease.¹ More recent data reinforces this: isolated anti-SSB positivity is associated with a significantly lower likelihood of Sjögren’s and may be a clinically insignificant finding in many patients.²

When anti-SSB appears alongside anti-SSA, it can add clinical context about disease severity or risk of certain complications. But if your lab results show anti-SSB positive and anti-SSA negative, that alone should not be read as evidence of Sjögren’s.³ This is one of the more common sources of confusion for patients who receive their results before seeing a specialist.

Labial Salivary Gland Biopsy

A lip biopsy is the most direct way to see whether the immune system is attacking the salivary glands. The procedure involves removing a few tiny glands from the inside of the lower lip under local anesthesia. A pathologist then examines the tissue under a microscope, looking for clusters of immune cells called lymphocytic foci. A “focus score” of one or more per four square millimeters of tissue is the traditional threshold for a positive result, and under the ACR-EULAR system this also earns three points, the same weight as anti-SSA.

The focus score catches about 82 percent of people who have Sjögren’s, which is good but not perfect.⁴ Recent research shows that looking at additional tissue features beyond just the focus score can improve accuracy. Features like lymphoepithelial lesions, a shift toward plasma cells, and germinal centers in the tissue each have very high specificity, meaning they almost never show up in people who don’t have the disease.⁴

One practical wrinkle with biopsy is that the number of glands collected matters. A study found that the reliability of the focus score improves as more glands are examined, with the diagnostic precision being markedly better when at least five glands are obtained compared to only two.⁵ If your biopsy report mentions only two glands were sampled, a borderline result deserves more skepticism than one based on a larger sample.

How the ACR-EULAR Criteria Pull Tests Together

The 2016 ACR-EULAR classification criteria are the current international standard. Rather than relying on a single test, they assign weighted scores to five items. Anti-SSA antibodies and a positive lip biopsy each earn three points. An abnormal ocular staining score earns one point. Very low unstimulated saliva flow earns one point. A low Schirmer’s test score earns one point. A total of four or more points classifies a patient as having primary Sjögren’s.

Validated across multiple populations, these criteria consistently show high sensitivity. In a Dutch cohort, the ACR-EULAR criteria reached 97 percent sensitivity and 83 percent specificity when compared to expert diagnosis.⁶ In a Japanese cohort of nearly 500 patients, sensitivity was about 95 percent, outperforming older classification systems.⁷ A Korean study found 100 percent sensitivity, though specificity dropped to about 82 percent, meaning the system sometimes flags people who may not actually have the disease.⁸

The pattern across these validation studies is consistent: the ACR-EULAR system catches more true cases than older criteria but sometimes overcalls the diagnosis. This trade-off makes sense for a disease where delayed diagnosis is a bigger clinical problem than overdiagnosis, since early treatment of complications and monitoring for lymphoma matter considerably.

Salivary Gland Ultrasound

Ultrasound of the major salivary glands has gained serious traction as a non-invasive alternative or supplement to biopsy. The technique looks for characteristic changes in the gland tissue, such as a speckled or inhomogeneous pattern caused by inflammatory infiltration. It requires no needles, no sedation, and can be done in the same office visit as a rheumatology appointment.

A systematic review and meta-analysis found that depending on the scoring system used, ultrasound achieved pooled sensitivity of roughly 75 to 84 percent and specificity of 88 to 95 percent for diagnosing Sjögren’s.⁹ Those numbers rival biopsy in some scoring ranges, which naturally raises the question of whether ultrasound could replace the biopsy altogether.

The answer, at least for now, is not quite. Research shows that substituting ultrasound for biopsy in the ACR-EULAR criteria substantially reduces the system’s overall accuracy. However, adding ultrasound as an additional item alongside biopsy keeps accuracy high and gives clinicians more flexibility.¹⁰ When ultrasound findings are combined with a positive anti-SSA result, the combination is highly predictive on its own, which can spare some patients from needing a biopsy at all.¹⁰

One caveat: ultrasound is operator-dependent, and scoring systems vary between centers. The meta-analysis noted that the simpler 0-to-4 scoring system had the highest specificity and least variation between studies, suggesting it may work best as a standardized tool.⁹

The Ocular and Oral Tests That Fill In the Gaps

The eye and mouth tests used in Sjögren’s evaluation are functional measures rather than disease-specific markers. They confirm that the glands are underperforming, but they can’t tell you why. Dry eyes and dry mouth have dozens of causes, so these tests rarely clinch a diagnosis on their own. They do, however, contribute the extra points needed under the classification criteria when higher-weighted tests aren’t conclusive.

The Schirmer’s test measures tear production by placing a small filter-paper strip under the lower eyelid for five minutes. It is simple but imprecise, with a sensitivity of only about 42 percent for Sjögren’s in some analyses.¹¹ Ocular surface staining, which uses dyes to reveal damage on the cornea and conjunctiva, performs somewhat better but still shows modest sensitivity in the range of 56 to 62 percent.¹² Lissamine green staining has shown better overall diagnostic performance, with specificity around 89 percent.¹¹

On the oral side, unstimulated whole saliva flow measurement asks you to spit into a collection tube for a set time. A flow rate at or below 0.1 mL per minute has been the traditional threshold, but this catches only about 43 percent of people with Sjögren’s while correctly excluding about 74 percent of those without it.¹³ An earlier study found the predictive value of very low flow to be reasonably high: among people with a result at or below 0.1 mL per minute, about 81 percent actually had the syndrome.¹⁴ Recent work suggests that adjusting the threshold or shortening the test time can improve the numbers, with very low flow below 0.05 mL per minute yielding specificity above 97 percent.¹⁵

The practical upshot: these tests are best understood as supporting evidence. They help establish that something is going wrong with your glands, and they can bump a borderline score over the diagnostic threshold. But a positive Schirmer’s or a low saliva flow rate alone doesn’t mean you have Sjögren’s.

When Standard Blood Tests Come Back Negative

Seronegative Sjögren’s, where patients have the disease but test negative for anti-SSA and anti-SSB, is one of the more frustrating diagnostic scenarios. These patients often wait years longer for a diagnosis because the most accessible screening test misses them. For this group, lip biopsy is typically the decisive test. One study of 166 patients found that about a third had biopsy results pointing to Sjögren’s, and biopsy findings correlated with other autoimmune markers and the presence of overlapping autoimmune conditions.¹⁶

There is also emerging evidence that some “seronegative” patients may actually have detectable autoantibodies if you look in different places. A study using a saliva-based immunoassay found anti-SSA/Ro-52 antibodies in 80 percent of patients whose standard blood tests were negative for anti-SSA.¹⁷ The technique used, called EFIRM, detected salivary autoantibodies in 94 percent of confirmed Sjögren’s patients overall. That said, it also found autoantibodies in 60 percent of people with dry-eye symptoms who did not have Sjögren’s, which raises questions about specificity and practical usefulness in its current form.¹⁷

Another approach to seronegative patients involves testing for anti-Ro52 and anti-Ro60 using more sensitive methods than standard ELISA. An immunodot assay identified anti-Ro52 antibodies in some biopsy-positive patients who had been negative on conventional testing, and reclassifying those patients by including Ro52/60 results changed the diagnosis in a meaningful fraction.¹⁸ The choice of laboratory assay, in other words, can itself affect whether a patient appears seropositive or seronegative.

MR Sialography and Advanced Imaging

Magnetic resonance sialography is a specialized MRI technique that images the salivary duct system without injecting contrast dye into the ducts, as older conventional sialography required. One study of 35 patients found that MR sialography matched conventional sialography findings in about 89 percent of cases, with both sensitivity and specificity reaching 100 percent for diagnosing Sjögren’s in that particular cohort.¹⁹ When conventional MRI of the gland tissue was combined with MR sialography, the positive diagnostic rate reached nearly 97 percent.²⁰

These numbers look impressive, but MR sialography is not widely available. It requires specific MRI sequences and radiologists experienced in interpreting salivary gland imaging. For most patients, ultrasound is a more practical first-line imaging choice, with MRI reserved for ambiguous cases or when there is concern about lymphoma or other structural complications.

Novel Autoantibodies for Early Detection

One of the more intriguing developments in Sjögren’s testing is the identification of autoantibodies that appear earlier than anti-SSA. Three in particular, directed against salivary proteins called SP1, CA6, and PSP, have shown up in patients with very early disease who have not yet developed anti-SSA or anti-SSB positivity. In one study, patients with dry eyes for less than two years and no dry mouth expressed none of the traditional autoantibodies, but 25 percent were positive for anti-SP1.²¹

The current thinking is that these newer autoantibodies may mark an early window of the disease, before the immune response shifts to target the Ro and La proteins. Data suggest they tend to fade as anti-SSA and anti-SSB become more prominent.²² If validated in larger studies, these markers could eventually allow diagnosis years before the disease becomes severe enough for traditional tests to catch. For now, testing for SP1, CA6, and PSP is not part of routine clinical practice, but some commercial panels already include them.

Telling Sjögren’s Apart from Its Mimics

Sjögren’s symptoms, especially dry eyes and a dry mouth, overlap with many other conditions. Medications, aging, radiation therapy, diabetes, sarcoidosis, and hepatitis C can all cause similar complaints. One condition that particularly mimics Sjögren’s is IgG4-related disease, which can cause identical-looking salivary gland swelling and dryness. A small study found that measuring certain inflammatory molecules in tears, specifically the ratios of IL-7 to IL-1α and IL-7 to IL-1β, could distinguish between the two diseases with sensitivity around 94 percent and specificity up to 90 percent.²³ This kind of testing is still experimental, but it highlights a real clinical need: the conditions that look like Sjögren’s sometimes require entirely different treatment.

For secondary Sjögren’s, which occurs alongside another autoimmune disease like lupus or rheumatoid arthritis, diagnosis gets even murkier. There are no universally accepted classification criteria for secondary Sjögren’s. Biopsy tends to be especially valuable in these patients because the tissue findings are relatively specific to Sjögren’s even when blood markers overlap with the primary condition.²⁴

Artificial Intelligence and the Future of Biopsy Reading

Even when a biopsy is performed, human interpretation of the tissue slides introduces variability. Two pathologists looking at the same biopsy can sometimes arrive at different focus scores. Researchers have started applying deep learning models to automate focus-score assessment from digitized biopsy slides. One recent model achieved an accuracy of about 85 percent, with sensitivity of 87 percent and specificity of 84 percent, performing better than earlier automated approaches.²⁵ The goal isn’t to replace pathologists but to reduce disagreements and speed up analysis, especially in settings where experienced specialists aren’t available.

Beyond biopsy automation, proteomic analysis of saliva and tears is under exploration as a potential non-invasive diagnostic avenue. Researchers have used mass spectrometry on salivary and tear samples from Sjögren’s patients to screen for protein signatures that could serve as novel biomarkers. The approach targets the disease’s actual sites of damage, the salivary and lacrimal glands, and could theoretically be used for both diagnosis and monitoring over time.²⁶ None of this is ready for routine use, but it represents a shift toward less invasive, more precise testing that could eventually change how the disease is diagnosed.